FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...

2024 saw the establishment of docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil as the preferred regimen for patients ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 32% phase transition success ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).

More research is needed to refine treatment strategies and identify predictive biomarkers for patient selection, according to researchers.

San Mateo, California Monday, December 30, 2024, 18:00 Hrs [IST] ...

Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma ...

INR:3656. cricket sa vs ind BeiGene's tislelizumab combined with chemotherapy has strong efficacy in treating gastric cancer/esophageal cancer How long can Cell ...

INR:0934. jai vs up kabaddi US$570 million! Leo obtains exclusive global license for new dermatitis and asthma drugs from companies on both sides of the Taiwan ...

INR:2435. charminar satta chart 2022 Review of clinical developments of China's Class 1 new drugs in February 2020 Tumor Therapeutic Fields + Chemother ...